Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Operating Leases (2020 - 2025)

Precision Biosciences (DTIL) has disclosed Operating Leases for 6 consecutive years, with $5.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 21.59% to $5.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.3 million, a 21.59% decrease, with the full-year FY2024 number at $6.4 million, down 17.08% from a year prior.
  • Operating Leases was $5.3 million for Q3 2025 at Precision Biosciences, down from $7.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $8.1 million in Q1 2021 to a low of $1.1 million in Q4 2022.
  • A 5-year average of $5.5 million and a median of $6.2 million in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: plummeted 78.0% in 2022, then surged 629.27% in 2023.
  • Precision Biosciences' Operating Leases stood at $4.8 million in 2021, then plummeted by 78.0% to $1.1 million in 2022, then soared by 629.27% to $7.7 million in 2023, then dropped by 17.08% to $6.4 million in 2024, then decreased by 17.3% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Operating Leases are $5.3 million (Q3 2025), $7.1 million (Q2 2025), and $6.0 million (Q1 2025).